Every year, Rare Disease Day (last day of February) highlights the significant challenges faced by patients living with rare conditions. Although each rare disease affects a small number of individuals, collectively they impact hundreds of millions worldwide. Many of these patients are children, and the effects of these diseases extend far beyond the patients themselves, placing considerable strain on families, caregivers, and society. The medical, emotional, and economic burdens are substantial, emphasizing the urgent need for innovative therapies and support systems.
In this context, Ampleia plays a central role as a catalyst for patient benefit. Its mission is to advance research programs in rare diseases, accelerating the development of innovative therapies and supporting earlier access to new treatment options. By collaborating closely with healthcare stakeholders, researchers, and patient communities, Ampleia works to turn scientific knowledge into tangible benefits for patients.
This February 2026 newsletter highlights recent initiatives, regulatory progress, and key clinical developments in the rare disease space, showcasing how coordinated efforts can speed access to therapies and improve the quality of life for patients and their families.
1. Clinical news & patient access
In February 2026, gene therapy headlines delivered both promise and caution. Ultragenyx gained FDA acceptance of its DTX401 BLA for GSDIa, with Priority Review and a PDUFA decision expected in August, while Neurogene earned Breakthrough Therapy designation for NGN‑401 in Rett syndrome after encouraging Phase 1/2 results. Yet outcomes can differ: uniQure’s AMT‑130 in Huntington’s disease faces a required randomized, sham‑controlled trial, underscoring that clinical success in gene therapy does not always translate into regulatory approval.
NMD Pharma A/S announced that its Phase 2a clinical trial of ignaseclant for Charcot‑Marie‑Tooth disease (CMT) types 1 and 2 — a rare neuromuscular disorder — did not meet its primary endpoint (change in the 6‑minute walk test), but secondary endpoints showed consistent and clinically meaningful improvements in muscle strength, motor performance, and patient‑reported outcomes. Based on these findings and a favorable safety profile, the company said it plans to accelerate further clinical development of ignaseclant and pursue additional studies in CMT as well as in related neuromuscular indications like spinal muscular atrophy and generalized myasthenia gravis.
Larimar Therapeutics announced that the FDA granted Breakthrough Therapy designation to nomlabofusp, a frataxin (FXN) protein replacement therapy with disease modifying potential, for the treatment of adults and children with Friedreich’s ataxia (FA), a rare inherited bone marrow failure disorder. The decision is based on clinical evidence suggesting meaningful benefit and aims to expedite development and review ahead of a planned BLA submission in mid‑2026.
Palvella Therapeutics announced that its Phase 3 SELVA clinical study of QTORIN™ 3.9% rapamycin anhydrous gel for treating microcystic lymphatic malformations (microcystic LMs) met its primary endpoint with a statistically significant improvement on the Microcystic Lymphatic Malformation Investigator Global Assessment (mLM‑IGA) and also achieved statistical significance on its key secondary and all four additional secondary efficacy endpoints. Based on these results, Palvella plans to submit a New Drug Application (NDA) to the FDA in the second half of 2026.
Feb. 26, 2026 — Ultragenyx — FDA accepts and grants priority review for DTX401 in GSDIa
Ultragenyx announced that the FDA has accepted its Biologics License Application (BLA) for DTX401, an AAV-based gene therapy for Glycogen Storage Disease Type Ia (GSDIa), a rare inherited metabolic disorder caused by deficiency of Glucose-6-phosphatase. The enzyme enables the liver to release glucose into the bloodstream; without it, patients cannot maintain normal blood sugar during fasting. Current management relies on strict dietary control—including frequent carbohydrate intake and uncooked cornstarch therapy—to stabilize glucose levels and prevent hypoglycemia. The FDA also granted Priority Review and set a target PDUFA Action Date of Aug. 23, 2026. If approved, DTX401 would be the first therapy designed to address the underlying cause of GSDIa.
Feb. 26, 2026 — Cerecin — Publication of Phase 1/2a study for CER‑0001 in rare pediatric epilepsy
Cerecin Inc. published results from a Phase 1/2a study of CER 0001 (tricaprilin) in infants with refractory epileptic spasms, a rare, drug-resistant form of early-onset epilepsy. CER 0001 is a metabolic therapy that provides medium-chain triglycerides, which the body converts into ketones—an alternative energy source for the brain. The therapy was generally well tolerated and showed meaningful efficacy: 50 % of participants (4 out of 8) experienced at least a 50 % reduction in seizure clusters, and 25 % (2 participants) achieved complete resolution. These results support further development in rare developmental and epileptic encephalopathies (DEE).
Feb. 26, 2026 — Positive opinion for Orphan Drug designation for SGX945 in Behçet’s disease
Soligenix, Inc. announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products provided a positive opinion on its request for Orphan Drug designation for SGX945 (dusquetide) for Behçet’s disease, a rare autoimmune condition. Once ratified, the designation will provide incentives and regulatory support as clinical development continues.
Feb. 26, 2026 — argenx — Vyvgart posts Phase 3 win in ocular myasthenia gravis
argenx announced positive topline results from the Phase 3 ADAPT OCULUS trial evaluating Vyvgart (efgartigimod) in ocular myasthenia gravis (oMG) — a rare autoimmune neuromuscular disease affecting eye muscles and causing ptosis and diplopia. Vyvgart is already an established FcRn‑blocking therapy approved for the treatment of generalized myasthenia gravis (gMG) in adults who are anti‑acetylcholine receptor antibody positive, and it has been further developed into subcutaneous formulations that are approved in multiple regions. It has also recently been approved for chronic inflammatory demyelinating polyneuropathy (CIDP) in Europe and other markets, marking expansion beyond its original gMG indication. The positive ADAPT OCULUS data showed meaningful improvements in disease‑specific outcome measures for oMG and bolster the case for a potential new indication beyond these current approvals.
Feb. 26–27, 2026 — Neurogene — FDA Breakthrough Therapy designation for NGN‑401 in Rett syndrome
Neurogene Inc. revealed that the FDA granted Breakthrough Therapy designation to NGN 401, an investigational gene therapy in late-stage development for Rett syndrome, based on interim Phase 1/2 data showing clinically meaningful, durable functional improvements across multiple neurological domains. The company initiated its registrational study (Embolden™) in Q4 2025, using a one-time total dose of 1 × 10¹⁵ vector genomes for all participants. These promising early results and the ongoing registrational trial support the potential for a transformative therapy in Rett syndrome.
Patient access news
Europe
European Parliament Proposes EU-Wide Rare Disease Action Plan
The European Parliament is stepping up for millions of Europeans living with rare diseases. In February 2026, the European Parliamentary Research Service (EPRS) published a key study calling for a coordinated EU Rare Disease Action Plan. The report highlights gaps in diagnosis, access to treatments, data sharing, and patient support that individual countries struggle to tackle alone.
The study proposes 31 concrete measures across six priority areas, from faster diagnosis and better research to more equitable access to therapies. European Reference Networks (ERNs) — cross-border clinical networks connecting specialists and resources — are seen as a cornerstone for improving care across the EU. The report emphasizes that EU-wide cooperation could reduce fragmentation, boost innovation, and make care more consistent for patients everywhere.
This study sets the stage for a formal EU strategy, giving hope for faster access to treatment and stronger support for the rare disease community.
Unites States
FDA Oversight: Balancing Speed and Safety in Rare Disease Therapies
The FDA is accelerating progress for patients with rare and ultra rare diseases. Its Accelerating Rare Disease Cures (ARC) Program continues to provide guidance and coordination to streamline drug development and help bring treatments to patients faster.
On February 23, 2026, the FDA issued draft guidance for individualized therapies, including gene editing and RNA-based treatments, where traditional large trials are not feasible. This new pathway allows developers to demonstrate effectiveness through smaller, controlled studies grounded in strong biological rationale. A public comment period is now open, giving patients and advocates a chance to provide input before finalization.
While accelerated pathways like the ARC program aim to bring treatments for rare diseases to patients faster, development can still be slowed by regulatory requirements. Even for rare conditions, the FDA may insist on randomized or sham-controlled trials (e.g., uniQure’s AMT‑130 in Huntington’s disease), multiple endpoints or extended follow-up to demonstrate durability, and robust safety data for novel gene therapies. Applying the same rules used for common diseases can be problematic: rare patient populations are small, heterogeneous, and often harder to recruit, making standard trial designs impractical or even ethically challenging. In these cases, insisting on conventional trial frameworks can delay access to life-saving therapies, highlighting the need for flexible, disease-specific approaches.
2. Financings & Partnerships
The FDA’s Priority Review Voucher (PRV) program, launched in 2007 to accelerate therapies for rare and neglected diseases, is becoming increasingly scarce—and incredibly valuable. Voucher prices have skyrocketed from $100 million in 2024, to $150 million+ in 2025, and hit $200 million+ in early 2026. A striking example: in February 2026, Cyprium Therapeutics (Fortress Biotech) sold a PRV for ~$205 million after FDA approval of ZYCUBO® for Menkes disease. With transferable vouchers in short supply, demand shows no sign of slowing.
Deal: Eton Pharmaceuticals, Inc. announced that it has licensed U.S. marketing rights to an ultra-rare disease product candidate currently under FDA review, expected to launch in mid-2026. Once approved, the therapy would be the first and only generic alternative for a condition affecting fewer than 100 patients in the United States. This strengthens Eton’s portfolio and commercial infrastructure in ultra-rare conditions.
Type: Licensing agreement (ultra-rare disease treatment)
Deal: Cyprium Therapeutics, majority-owned by Fortress Biotech, sold its FDA Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million following the approval of ZYCUBO® for Menkes disease, a rare pediatric neurodegenerative disorder. The sale will fund ongoing rare disease programs and provide strategic flexibility for future development.
Type: Priority Review Voucher sale (strategic regulatory asset monetization)
Feb. 26, 2026 — Palvella Therapeutics — $200 M upsized public offering to fund rare disease pipeline
Deal: Palvella Therapeutics, Inc. completed an upsized registered public offering of 1.6 million shares at $125 per share, raising approximately $200 million. Proceeds will support its pipeline of therapies for microcystic lymphatic malformations and other dermatological rare diseases, along with ongoing clinical and regulatory initiatives.
Type: Public equity financing (rare disease biotech)
3. Research breakthroughs
Erythropoietin improves ASD‑like behaviors in a Zbtb20‑haploinsufficient Primrose syndrome mouse model
A study published in JCI Insight reports on a new animal model for Primrose syndrome, an extremely rare neurodevelopmental disorder caused by heterozygous loss of the transcription factor ZBTB20. Researchers conducted an exhaustive behavioral and brain structural characterization of Zbtb20^+/‑ mice, which mimic key aspects of the human condition — including impaired social interaction, reduced communication, repetitive behaviors, decreased cognitive flexibility, hyperactivity, and altered brain morphology (enlarged hippocampus and cerebellum). MRI and post‑mortem analyses confirmed increased brain volumes in these mice, aligning with aspects of macro‑/megaencephaly seen in human cases.
Importantly, the research team tested recombinant human erythropoietin (rhEPO) as a potential therapeutic approach, building on prior observations that EPO increases ZBTB20 expression in hippocampal neurons. After 3 weeks of alternate‑day rhEPO injections, treated Zbtb20^+/‑ mice showed substantial improvements in sociability, cognitive flexibility, working memory, and exploratory motivation compared to placebo‑treated counterparts, suggesting that EPO may mitigate some core symptoms of Primrose syndrome.
This work not only establishes a construct‑valid animal model for further laboratory investigation of Primrose syndrome but also identifies rhEPO as a promising candidate for future translational studies, potentially informing therapeutic strategies for related rare autism spectrum and intellectual disability disorders.
New LARS2 Variants Expand Understanding of Perrault Syndrome
Researchers have identified two previously unreported variants in the LARS2 gene in patients with Perrault syndrome, a rare autosomal recessive disorder causing sensorineural hearing loss (SNHL) and primary ovarian insufficiency (POI). The first variant, c.235‑2A>G, disrupts a splice site before exon 4, leading to exon skipping and abnormal transcripts, which interfere with mitochondrial translation. The second, c.1661T>C (p.Val554Ala), is a missense change predicted to destabilize the protein. Both variants were confirmed by family co‑segregation studies and classified as likely pathogenic. Clinically, the female patient with c.235‑2A>G had profound SNHL, POI, and mild developmental delays, while the male patient with c.1661T>C showed severe SNHL with an atypical audiogram. These findings expand the genotype–phenotype spectrum of Perrault syndrome and provide key insights for molecular diagnosis, patient management, and genetic counselling. This study highlights the value of combining genomic sequencing with functional assays to uncover previously undetected pathogenic variants, advancing early diagnosis and supporting the development of targeted strategies for rare genetic disorders.
Upcoming events
📅 March 5–6, 2026 — Advancement of Treatments for Rare Diseases 2026 — Nicosia, Cyprus
European meeting focused on regulatory collaboration, research innovation, access, and therapeutic development for rare diseases.
📅 March 10–14, 2026 — Annual Clinical Genetics Meeting (ACMG 2026) — Baltimore, MD, USA
The premier clinical genetics meeting featuring substantial content on rare disease diagnostics, genomics, precision medicine, and gene therapy advances.
📅 May 18–19, 2026 — 15th World Rare Diseases Congress 2026 — Prague, Czech Republic
Global forum covering research, policy, and clinical care for rare and orphan diseases, bringing together scientists, clinicians, advocates, industry, and regulators.
📅 June 3–4, 2026 — European Conference on Rare Diseases & Orphan Products (ECRD 2026) — Prague, CZ & Online
The flagship European policy and advocacy event for rare diseases, led by EURORDIS, addressing healthcare access, research, holistic care, and patient engagement.
📅 June 9–11, 2026 — World Orphan Drug Congress USA 2026 — Boston, MA, USA
One of the largest global gatherings dedicated to rare and orphan drug development, bringing together industry leaders, regulators, investors, and patient advocates.
📅 June 17–18, 2026 — 7th International Conference on Rare Diseases (RARE2026) — Kraków, Poland
Scientific conference covering gene therapy, omics, newborn screening, and translational research with global participation and expert speakers in the rare disease field.
📅 September 9–10, 2026 — Clinical Trials in Rare Diseases Conference 2026 — Princeton Marriott at Forrestal, Princeton, NJ, USA
Focused on innovative clinical trial design, patient recruitment, and regulatory strategies for rare disease therapeutics, connecting academia, biotech, and regulators.
📅 September 14–15, 2026 — 2nd European Congress on Rare Diseases and Orphan Drugs 2026 — London, United Kingdom
International forum featuring researchers, clinicians, policymakers, and pharmaceutical experts discussing new advances in diagnosis, orphan drug development, and health policy.
📅 October 22–23, 2026 — 4th International Conference on Rare Diseases and Orphan Drugs 2026 — Barcelona, Spain
Global scientific conference themed “From Discovery to Cure: Transforming Rare Disease Care,” highlighting cutting‑edge research, therapeutic innovation, and patient‑centered care models.
📅 October 25–27, 2026 — NORD Rare Diseases & Orphan Products Breakthrough Summit 2026 — Washington, DC, USA
Hosted by the National Organization for Rare Disorders (NORD), this premier U.S. summit unites patients, researchers, regulators, and biotech innovators to accelerate progress in rare disease treatments and policy.